Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales [Yahoo! Finance]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Yahoo! Finance
KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update of additional recent developments in the fast-moving glucagon-like peptide-1 ("GLP-1") oral (or "pill") market. The GLP-1 oral pill sector is growing much faster in 2026 than expected, and faster than the pre-existing GLP-1 injectable sector. The industry's first-ever GLP-1 pill for weight loss, Wegovy ® , was approved by the US Food and Drug Administration ("FDA") on December 22, 2025 and launched in the US in January 2026. Prior to that, Rybelsus ® was the only FDA approved GLP-1 drug available in pill form, but it was approved for diabetes control and only used secondarily (or, "off label") for weight loss. Within less than the first two months of its launch, Novo Nordisk ® had disclosed that over 600,000 prescriptions for the Wegovy ® pill had been written , and will report on its first-quart
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Launches New Study to Examine Next-Generation GLP-1 DrugsACCESS Newswire
- Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- Lexaria's Robust Patent Portfolio Continues to Grow [Yahoo! Finance]Yahoo! Finance
- Lexaria Bioscience: Oral Drug Delivery Technology Targets Next-Gen Weight Loss Market [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Lexaria Bioscience: Improving Oral Weight-Loss Drug Tolerability [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
LEXX
Sec Filings
- 4/13/26 - Form 10-Q
- 3/18/26 - Form 4
- 2/6/26 - Form 8-K
- LEXX's page on the SEC website